三諾生物(300298.SZ)：子公司擬不超1.5億元參與增資上藥雲健康項目
格隆匯 10 月 16日丨三諾生物(300298.SZ)公佈，公司全資子公司三諾健康管理有限公司(“三諾健康”)擬作為意向投資者以自有資金不超過1.5億元人民幣參與增資上海醫藥大健康雲商股份有限公司(“上藥雲健康”)項目。如此次增資完成，三諾健康將持有上藥雲健康4.95%股權，三諾健康將加強與上藥雲健康的業務合作，把產品和服務延伸至更多的用於糖尿病患者慢病管理的產品和服務。根據上藥雲健康在上海聯合產權交易所的增資項目掛牌信息(上海醫藥大健康雲商股份有限公司增資項目，項目編號：G62020SH1000054)，上藥雲健康現註冊資本為約13.33億元，投前估值為20億元人民幣，擬新增註冊資本人民幣約6.89億元，增資的價格為每單位註冊資本1.5元，溢價部分計入公司資本公積。
此次上藥雲健康增資項目擬共新增投資人3-6家，三諾健康參與項目所需資金來源為自有資金。此次增資將按照上藥雲健康增資項目掛牌方案予以實施，掛牌截止日為2020年11月16日，目前公司尚未繳納保證金，尚未簽署相關協議。
三諾健康作為公司的全資子公司，堅持深耕以糖尿病為主的慢病管理領域，旨在建設糖尿病全程一體化數字管理平台，將整合政府、醫療機構、藥企、器械企業、藥店、商保企業、健康管理機構多方資源，搭建糖尿病等慢病管理生態系統，讓患者能夠進行準確、及時、可視化地進行自我健康管理，方便醫護人員和健康顧問提供有針對性的診療和指導。上藥雲健康的實際控股人為上海醫藥，且其擁有全國專業藥房DTP網絡，已形成較為完整的資質條件和業務體系。此次增資上藥雲健康，可以依託雙方資源優勢，促進公司積極向糖尿病及相關慢病管理及服務領域拓展，構建“醫+藥+險+管理”的生態服務閉環體系。同時，公司通過加強與上藥雲健康的業務合作，拓展完善現有產品渠道，把產品線延伸至更多的用於糖尿病患者慢病管理的產品和服務，實現公司整體基於糖尿病及相關慢病的管理與服務領域業務的開拓。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
